Korean Drug Co. Ltd
Korean Drug Co., Ltd. manufactures and sells medicines for treating various diseases in South Korea. The company offers Medicines for urinary tract disease, digestive system, circulatory system, psychonervous system, central nervous system, respiratory system, and skin and subcutaneous system; and antivirals, antibiotics, antifungals, antipyretic, analgesis, anti-inflammatory, and other products.… Read more
Market Cap & Net Worth: Korean Drug Co. Ltd (014570)
Korean Drug Co. Ltd (KQ:014570) has a market capitalization of $29.56 Million (₩43.28 Billion) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #26876 globally and #1751 in its home market, demonstrating a 1.27% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Korean Drug Co. Ltd's stock price ₩4000.00 by its total outstanding shares 10819663 (10.82 Million).
Korean Drug Co. Ltd Market Cap History: 2015 to 2026
Korean Drug Co. Ltd's market capitalization history from 2015 to 2026. Data shows change from $31.76 Million to $29.56 Million (-0.92% CAGR).
Index Memberships
Korean Drug Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$166.01 Billion | 0.01% | #946 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$166.01 Billion | 0.01% | #946 of 1384 |
Weight: Korean Drug Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Korean Drug Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Korean Drug Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Korean Drug Co. Ltd's market cap is 0.00 times its annual revenue
0.84x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.01x
Korean Drug Co. Ltd's market cap is 0.01 times its annual earnings
11.15x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $31.76 Million | $47.39 Billion | $1.77 Billion | 0.00x | 0.02x |
| 2016 | $42.75 Million | $55.31 Billion | $5.05 Billion | 0.00x | 0.01x |
| 2017 | $46.57 Million | $55.40 Billion | $4.68 Billion | 0.00x | 0.01x |
| 2018 | $48.41 Million | $52.03 Billion | $6.56 Billion | 0.00x | 0.01x |
| 2019 | $48.93 Million | $55.53 Billion | $3.90 Billion | 0.00x | 0.01x |
| 2020 | $71.14 Million | $66.79 Billion | $7.36 Billion | 0.00x | 0.01x |
| 2021 | $62.88 Million | $74.47 Billion | $9.04 Billion | 0.00x | 0.01x |
| 2022 | $56.39 Million | $79.98 Billion | $11.81 Billion | 0.00x | 0.00x |
| 2023 | $53.06 Million | $81.37 Billion | -$4.92 Billion | 0.00x | N/A |
| 2024 | $33.95 Million | $73.00 Billion | $3.00 Billion | 0.00x | 0.01x |
Competitor Companies of 014570 by Market Capitalization
Companies near Korean Drug Co. Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Korean Drug Co. Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Korean Drug Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Korean Drug Co. Ltd's market cap moved from $31.76 Million to $ 29.56 Million, with a yearly change of -0.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩29.56 Million | -6.98% |
| 2025 | ₩31.77 Million | -6.42% |
| 2024 | ₩33.95 Million | -36.00% |
| 2023 | ₩53.06 Million | -5.92% |
| 2022 | ₩56.39 Million | -10.31% |
| 2021 | ₩62.88 Million | -11.62% |
| 2020 | ₩71.14 Million | +45.40% |
| 2019 | ₩48.93 Million | +1.07% |
| 2018 | ₩48.41 Million | +3.96% |
| 2017 | ₩46.57 Million | +8.93% |
| 2016 | ₩42.75 Million | +34.59% |
| 2015 | ₩31.76 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Korean Drug Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $29.56 Million USD |
| MoneyControl | $29.56 Million USD |
| MarketWatch | $29.56 Million USD |
| marketcap.company | $29.56 Million USD |
| Reuters | $29.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.